Increase in Prevalence of Chronic Diseases Expected to Drive Global Next-Generation Antibody Therapeutics Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit The next-generation antibody is intended to be more specific & more potent than the traditional monoclonal antibodies. Next-generation antibody therapeutics is used for the treatment of different medical conditions such as infectious diseases, cancer and autoimmune diseases to improve the current properties of therapeutic antibodies. According to study, “Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030” the key companies operating in the global next-generation antibody therapeutics market are Amgen Inc., Kyowa Hakko Kirin Co. Ltd., AstraZeneca PLC., F. Hoffmann-La Roche Ltd., Bayer AG, Seattle Genetics Inc., Biogen, Takeda Pharmaceuticals Company Limited, Bristol-Myers Squibb Company, ImmunoGen Inc., Dyax Corp., Pfizer Inc. and Xencor Inc. The key companies have either set up their manufacturing services or are planning to start new stipulation in the dominated region in the upcoming years. Based on type, next-generation antibody therapeutics market is segmented as Antibody Fragments and Antibody-Like Proteins (AF & ALPs), Antibody Drug Conjugates (ADCs), Fc Engineered Antibodies, Bispecific Antibodies (BsAbs) and Biosimilar Antibody (Ab) Products. The ADC technology consolidates the cytotoxic potential of chemotherapy and profitable characteristics of antibodies that prompts high specificity and efficiency of ADCs. Based on application, market is segmented as autoimmune/inflammatory and oncology. The oncology segment is predicted to witness higher growth rate due to rise in incidence of cancer during the forecast period. In addition, based on end-user, market is segmented as clinics, hospitals and others. The next-generation antibody therapeutics market is driven by increase in prevalence of chronic diseases, followed by rise in number of collaborations for Research & Development (R&D) in next-generation antibody therapeutics, growth in production & invention of new medicines, and increase in applications of such therapies. However, stringent regulatory related to antibody therapeutics and lengthy approval processes and higher costs of therapeutics may impact the market. Moreover, growth in technological advancements in antibody therapeutics, rise in demand for better healthcare services and growth in biosimilar antibodies & engineered antibodies are key opportunities for market. Furthermore, increase in popularity of ADC technology is a key trend for market. Based on geography, the North-American region holds major share in global next-generation antibody therapeutics market owing to increase in investment on R&D of the next generation antibody drugs by governments in the region. The European and Asian-Pacific regions are estimated to witness higher growth rate due to surge in the geriatric population, rise in healthcare expenditure coupled with increase in government initiatives over the forecast period. It is expected that future of the global market will be optimistic caused by increase in prevalence of chronic diseases and growth in improvement of life sciences research infrastructure during the forecast period. The global next-generation antibody therapeutics market is valued around at US $4.69 million in 2019 and is anticipated to grow at US $14.26 million by 2030, at a CAGR of 13.69% during the forecast period. For More Information, Click on the Link Below:- Global Next-Generation Antibody Therapeutics Market Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249 Tags: Antibody-Drug Conjugates Market, Biogen Next Generation Antibody Therapeutics Market Share Revenue, Bispecific Antibody Therapeutics Market, China Next Generation Antibody Therapeutics Market, Covid-19 on Next Generation Antibody Therapeutics Industry, Covid-19 on Next Generation Antibody Therapeutics Market, Europe Next Generation Antibody Therapeutics Market, Global Next Generation Antibody Therapeutics Industry, Global Next Generation Antibody Therapeutics Industry Research Report, Global Next Generation Antibody Therapeutics Market, Global Next Generation Antibody Therapeutics Market Outlook, Global Next Generation Antibody Therapeutics Market Research Report, Global Next Generation Antibody Therapeutics Market Shares, ImmunoGen Inc Next Generation Antibody Therapeutics Market Share, India Next Generation Antibody Therapeutics Market, Japan Next Generation Antibody Therapeutics Market, Market Research Report of Global Next Generation Antibody Therapeutics, Next Generation Antibody Therapeutics Market, Next Generation Antibody Therapeutics Market Analysis, Next Generation Antibody Therapeutics Market Demand, Next Generation Antibody Therapeutics Market Dynamics, Next Generation Antibody Therapeutics Market Forecast, Next Generation Antibody Therapeutics Market Trends, Next-Generation Antibody Therapeutics Market Key Players, Seattle Genetics Inc Next Generation Antibody Therapeutics Market Share, US Next Generation Antibody Therapeutics Market, Xencor Inc Next Generation Antibody Therapeutics Market Revenue